Acute myeloid leukaemia triggering via CD40 induces leukocyte chemoattraction and cytotoxicity against allogenic or autologous leukemic targets

Leukemia

Volumn 14, Issue 1, 2000, Pages 123-128

  Costello, R T ^a,b   Mallet, F ^b   Chambost, H ^c   Sainty, D ^a   Arnoulet, C ^a   Gastaut, J A ^a   Olive, D ^b,d  

^a Dept d'Hématologie ^*  (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c TIMONE HOSPITAL   (France)

^d INSERM   (France)

Author keywords

Acute myeloid leukemia; CD40; Chemokines; IL 12; Immunotherapy

Indexed keywords

CD40 ANTIGEN; CHEMOATTRACTANT; INTERLEUKIN 12; INTERLEUKIN 8; RANTES; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN PRESENTING CELL; ARTICLE; CELL STIMULATION; CYTOKINE RELEASE; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; SUPERNATANT; T LYMPHOCYTE;

EID: 0033971173     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401628     Document Type: Article

References (51)

1. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994; 15: 406-411.
2. + T-cell responses. Immunol Today 1996; 17: 410-414.
3. Stout RD, Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today 1996; 17: 487-491.
4. Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995; 92: 8200-8204.
5. Van den Hove LE, Van Goll SW, Vandenberghe P, Bakkus M, Thielemans K, Boogaerts MA, Ceuppens JL. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by upregulation of CD80 and CD86 costimulatory molecules. Leukemia 1997; 11: 572-580.
6. Costello RT, Gastaut J-A, Olive D. What is the real role ot CD40 in cancer immunotherapy? Immunol Today 1999 (in press).
7. Amadori S, Venditti A, Del Poeta G, Stasi R, Buccisano F, Bruno A, Tamburini A, Cox MC, Maffei L, Aronica G, Simone MD, Adorno G, Masi M, Tribalto M, Papa G. Minimally differentiated acute myeloid leukemia (AML-M0): a distinct clinico-biologic entity with poor prognosis. Ann Hematol 1996; 72: 208-215.
8. Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuynck H, Van Orshoven A, Criel A, Stul M, Dal Cin P, Hernandez J et al. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Blood 1995; 85: 3688-3694.
9. Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T, Cox C, Dallapiccola B, Papa G. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood 1994; 83: 1619-1625.
10. Sempere A, Jarque I, Guinot M, Palau J, Garcia R, Sanz GF, Gomis F, Perez-Sirvent ML, Senent L, Sanz MA. Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases. Leuk Lymphoma 1993; 12: 103-108.
11. Cadwell FJ, Burns CP, Dick FR, Jones MP, Heckman KD, Weiner GJ, Goeken JA. Minimally differentiated acute leukemia. Leukemia Res 1993; 17: 199-208.
12. +/CD38 leukemic progenitors. Leukemia 1999 (in press).
13. Costello RT, Mallet F, Sainty D, Maraninchi D, Gastaut JA, Olive D. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur J Immunol 1998; 28: 90-103.
14. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick H, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 626-629.
15. Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA. Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. Bood 1987; 70: 1400-1406.
16. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 1991; 78: 325-329.
17. Costello R, Cerdan C, Pavon C, Brailly H, Hurpin C, Mawas C, Olive D. The CD2 and CD28 adhesion molecules induce long-term autocrine proliferation of CD4' T cells. Eur J Immunol 1993; 23: 608-613.
18. Yoshida T, Imai T, Kakizaki M, Nishimura M, Takagi S, Yoshie O. Identification of single C motif-1/lymphotactic receptor XCR1. J Biol Chem 1998; 273: 16551-16554.
19. Anonymous. SPSS User's Guide. SPSS Inc: Paris, 1993.
20. Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity 1998: 9: 1-11.
21. Soiffer RJ, Robertson MJ, Murray C, Cochran K, Ritz J. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 1993; 82: 2790-2796.
22. Geldhof AB, Moser M, Lespagnard L, Thielemans K, De Baetselier P. Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 1998; 91: 196-206.
23. van Parijs L, Perez VL, Biuckians A, Maki R, London CA, Abbas AK. Role of interleukin 12 and costimulators in T cell anergy in vivo. J Exp Med 1997; 186: 1119-1128.
24. Sogn JA. Tumor immunology: the glass is half full. Immunity 1998; 9: 757-763.
25. Costello RT, Gastaut J-A, Olive D. Tumour escape from immune surveillance. Arch Immunol Ther Exp (Warsz) 1999; 47: 83-88.
26. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 1999; 20: 158-160.
27. Fenton RG, Longo DL. Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes. J Natl Cancer Inst 1997; 89: 801-810.
28. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
29. Zlotnik A, Morales J, Hedrick JA. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 1999; 19: 1-47.
30. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19: 568-574.
31. Vinante F, Rigo A, Tecchio C, Patuzzo C, Ricetti MM, Morosato L, Cassatella MA, Chilosi M, Pizzolo G. Preferential release of high amounts of interleukin-8 by myeloid blasts showing monocytic differentiation. Haematologica 1996; 81: 195-200.
32. Vinante F, Rigo A, Vincenzi C, Ricetti MM, Marrocchella R, Chilosi M, Cassatella MA, Bonazzi L, Pizzolo G. IL-8 mRNA expression and IL-8 production by acute myeloid leukemia cells. Leukemia 1993: 7: 1552-1556.
33. Terui Y, Ikeda M, Tomizuka H, Kasahara T, Ohtsuki T, Uwai M, Mori M, Itoh T, Tanaka M, Yamada M, Shimamura S, Ishizaka Y, Ikeda K, Ozawa K, Miura Y, Hatake K. Activated endothelial cells induce apoptosis in leukemic cells by endothelial interleukin-8. Blood 1998: 92: 2672-2680.
34. Terui Y, Ikeda M, Tomizuka H, Kasahara T, Ohtsuki T, Uwai M, Mori M, Itoh T, Tanaka M, Yamada M, Shimamura S, Iura Y, Hatake K. Identification of a novel apoptosis-inducing factor derived from leukemic cells: endothelial interleukin-8, but not monocyte-derived, induces apoptosis in leukemic cells. Biochem Biophys Res Commun 1998; 243: 407-411.
35. Vinante F, Rigo A, Cassatella M, Pizzolo G. Interleukin-8 in acute myeloid leukemia. Blood 1999; 93: 1437-1442.
36. Reisser D, Lejeune P, Lagadec P, Onier N, Dasilva C, Lindley I, Jeannin JF. Interleukin-8 antitumour effect is associated with a local infiltration but not with a systemic activation of T lymphocytes. Anticancer Res 1994; 14: 977-979.
37. Turner L, Ward SG, Sansom D, Westwick J. A role for RANTES in T lymphocyte proliferation. Biochem Soc Trans 1996; 24: 93S.
38. Hartveit F. Breast cancer: poor short-term prognosis in cases with moderate lymphocyte infiltration at the tumour edge: a preliminary report. Oncol Rep 1998; 5: 423-426.
39. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-1310.
40. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74: 43-47.
41. Umansky V, Schirrmacher V, Rocha M. New insights into tumor-host interactions in lymphoma metastasis. J Mol Med 1996; 74: 353-365.
42. Trinchieri G. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008-4027.
43. Trinchieri G. Function and clinical use of interleukin-12. Curr Opin Hematol 1997; 4: 59-66.
44. Kelleher P, Knight SC. IL-12 increases CD80 expression and the stimulatory capacity of bone marrow-derived dendritic cells. Int Immunol 1998; 10: 749-755.
45. Mogi S, Ebata T, Setoguchi Y, Fujime M, Heike Y, Kohsaka T, Yagita H, Okumura K, Azuma M. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2. Clin Cancer Res 1998; 4: 713-720.
46. Chen PW, Geer DC, Podack ER, Ksander BR. Tumor cells transtected with B7-1 and interleukin-12 cDNA induce protective immunity. Ann NY Acad Sci 1996; 795: 325-327.
47. Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 1995; 55: 4980-4987.
48. + T cell tolerance to T cell priming through in vivo ligation of CD40. Nature Med 1999; 5: 780-787.
49. French R, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T cell response that eradicates lymphoma and bypasses T cell help. Nature Med 1999; 5: 548-553.
50. Diehl L, den Boer ATh, Schoenberger SP, Van der Voort EIH, Schumacher TNM, Melief CJM, Offringa R, Toes REM. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Med 1999; 5: 774-779.
51. Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG, Agathanggelou A, Cullen N, Macartney J, Fanslow WC, Murphy WJ. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999; 93: 2999-3007.